Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627 | CEO | August 18, 2026 | August 20, 2026 |
| Tourmaline Bio, Inc.TALS · Entity 15643 | Director | June 13, 2023 | June 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ROCKET PHARMACEUTICALS, INC.
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,056,594 |
Reported balance
After 2026-08-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-18 · Sale · Disposed 2,293 · Balance 1,056,594 F1: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 207,897 |
Reported balance
Holding disclosure · report date 2026-08-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 207,897 |
| Common StockSEC Table I · non-derivative | IndirectBy Gaurav D. Shah Irrevocable Trust | 198,341 |
Reported balance
Holding disclosure · report date 2026-08-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 198,341 |
Filing footnotes · ownership attribution and instrument terms
F1: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
F2: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.
Tourmaline Bio, Inc.
Report date June 13, 2023 · Filed June 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.54 · Expires 2033-06-13 | Direct | 20,500 |
Reported balance
After 2023-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-13 · Grant · Acquired 20,500 · Balance 20,500 F1: The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2026 Filed Aug 20, 2026 21:25 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 2,293 | $3.38 | $7,752.63 |
DisclosureSEC source: 0001140361-26-033913 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,056,594 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 21:52 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 2,837 | $3.38 | $9,591.90 |
DisclosureSEC source: 0001140361-26-033417 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,058,887 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| May 21, 2026 Filed May 26, 2026 23:47 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionStock Option (Right to Buy) · Derivative | 76,490 | $1.69 Strike: $1.69 | $129,344.59 |
DisclosureSEC source: 0001140361-26-022894 · form4.xml · derivative · entry 5 Shah Gaurav · CIK 0001725922 · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,490 shares Expires 2027-04-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option represents a right to purchase a total of 76,490 shares of the Issuer's Common Stock, one-third of which became fully vested and exercisable on April 12, 2018, with the remaining two-thirds vesting in equal quarterly installments over the following two years. Read SEC document |
| May 21, 2026 Filed May 26, 2026 23:47 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 55,684 | $3.09 | $171,840.82 |
DisclosureSEC source: 0001140361-26-022894 · form4.xml · nonDerivative · entry 2 Shah Gaurav · CIK 0001725922 · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,061,724 F1 · security: Holdings include Restricted Stock Units that convert to common stock on a one-for-one basis. F3 · kind: Represents shares sold by the Reporting Person in order to pay the exercise price of a Stock Option and to cover certain taxes in connection with the exercise of the Stock Option. F4 · price: Represents a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $3.08 to $3.105. The Reporting Person has provided the issuer and will provide any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F1 · balance_after: Holdings include Restricted Stock Units that convert to common stock on a one-for-one basis. Read SEC document |
| May 21, 2026 Filed May 26, 2026 23:47 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 76,490 | $1.69 | $129,344.59 |
DisclosureSEC source: 0001140361-26-022894 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,117,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Holdings include Restricted Stock Units that convert to common stock on a one-for-one basis. F2 · security: Represents shares received upon exercise of a Stock Option in advance of the expiration of such Stock Option. F1 · balance_after: Holdings include Restricted Stock Units that convert to common stock on a one-for-one basis. Read SEC document |
| May 19, 2026 Filed May 21, 2026 20:06 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 2,409 | $3.01 | $7,260.73 |
DisclosureSEC source: 0001140361-26-022447 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,040,918 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| May 13, 2026 Filed May 14, 2026 20:19 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 2,728 | $3.61 | $9,837.17 |
DisclosureSEC source: 0001140361-26-021315 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,043,327 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:26 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 5,990 | $3.34 | $19,994.62 |
DisclosureSEC source: 0001140361-26-006326 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,046,055 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 12,279 | $3.31 | $40,668.05 |
DisclosureSEC source: 0001140361-26-006043 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,052,045 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 870,648 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001140361-26-005412 · form4.xml · derivative · entry 4 Shah Gaurav · CIK 0001725922 · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 870,648 Underlying: Common Stock · 870,648 shares Expires 2036-02-11 F3 · derivative.exercise_date: This option represents a right to purchase a total of 870,648 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 286,028 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-005412 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,064,324 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · shares: Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years. F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 6,276 | $2.98 | $18,721.31 |
DisclosureSEC source: 0001140361-25-042855 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 778,296 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:00 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Tax withholdingCommon Stock | 2,234 | $3.05 | $6,813.70 |
DisclosureSEC source: 0001140361-25-032089 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 784,572 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were withheld by the Company in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 2,253 | $6.45 | $14,522.84 |
DisclosureSEC source: 0001140361-25-020160 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 786,806 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| May 16, 2025 Filed May 20, 2025 20:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 3,621 | $6.53 | $23,637.89 |
DisclosureSEC source: 0001140361-25-019899 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 789,059 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| April 10, 2025 Filed Apr 14, 2025 22:57 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | PurchaseCommon Stock | 20,000 | $5.08 | $101,600.00 |
DisclosureSEC source: 0001140361-25-013804 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 792,680 Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 21:01 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 16,303 | $10.58 | $172,485.74 |
DisclosureSEC source: 0001140361-25-005844 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 772,680 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 21:01 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 243,345 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0001140361-25-004296 · form4.xml · derivative · entry 4 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,345 Underlying: Common Stock · 243,345 shares Expires 2035-02-11 F2 · derivative.exercise_date: This option represents a right to purchase a total of 243,345 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 11, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 21:01 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 81,655 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-004296 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 788,983 F1 · security: Represent RSUs that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on February 11, 2026, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 11,091 | $13.05 | $144,781.91 |
DisclosureSEC source: 0001140361-24-047755 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 707,328 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 20:26 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 9,650 | $18.50 | $178,563.60 |
DisclosureSEC source: 0001140361-24-037932 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 718,419 F1 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| May 16, 2024 Filed May 20, 2024 20:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 9,790 | $23.35 | $228,596.50 |
DisclosureSEC source: 0001140361-24-026878 · form4.xml · nonDerivative · entry 5 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 728,069 F4 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| May 14, 2024 Filed May 20, 2024 20:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 9,683 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-026878 · form4.xml · derivative · entry 9 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,785 Underlying: Common Stock · 9,683 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F2 · derivative.expiration_date: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| May 14, 2024 Filed May 20, 2024 20:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 7,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-026878 · form4.xml · derivative · entry 8 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,940 Underlying: Common Stock · 7,979 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents RSUs initially granted on February 14, 2022. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F1 · derivative.exercise_date: Represents RSUs initially granted on February 14, 2022. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F1 · derivative.expiration_date: Represents RSUs initially granted on February 14, 2022. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| May 14, 2024 Filed May 20, 2024 20:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 9,683 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-026878 · form4.xml · nonDerivative · entry 2 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 646,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| May 14, 2024 Filed May 20, 2024 20:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 7,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-026878 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 636,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents RSUs initially granted on February 14, 2022. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 01:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 196,336 | $0.00 Strike: $30.01 | $0.00 |
DisclosureSEC source: 0001140361-24-008886 · form4.xml · derivative · entry 5 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,336 Underlying: Common Stock · 196,336 shares Expires 2034-02-16 F5 · derivative.exercise_date: This option represents a right to purchase a total of 196,336 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 16, 2025, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 01:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 66,577 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-008886 · form4.xml · nonDerivative · entry 2 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 621,339 F1 · security: The shares beneficially owned by the reporting person are subject to a lock-up agreement dated September 12, 2023 (the "Lock-Up Agreement"). F4 · security: Represent RSUs that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on February 16, 2025, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 01:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 20,272 | $29.84 | $604,875.94 |
DisclosureSEC source: 0001140361-24-008886 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 554,762 F1 · security: The shares beneficially owned by the reporting person are subject to a lock-up agreement dated September 12, 2023 (the "Lock-Up Agreement"). F2 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person. F3 · shares: The shares of common stock were sold by the Reporting Person pursuant to an exemption to the Lock-Up Agreement in order to pay tax withholding obligations in connection with the vesting of RSUs. Notwithstanding the sales reported on this Form 4, the securities beneficially owned by the reporting person remain subject to the terms of the Lock-Up Agreement. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 38,849 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-008359 · form4.xml · derivative · entry 5 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,468 Underlying: Common Stock · 38,849 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. F4 · derivative.expiration_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 7,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-008359 · form4.xml · derivative · entry 4 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,919 Underlying: Common Stock · 7,979 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. F3 · derivative.expiration_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 46,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-008359 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 575,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. F1 · shares: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. Read SEC document |
| November 14, 2023 Filed Nov 17, 2023 00:09 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 7,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-053709 · form4.xml · derivative · entry 4 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,898 Underlying: Common Stock · 7,979 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. F3 · derivative.expiration_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| November 14, 2023 Filed Nov 17, 2023 00:09 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 7,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-053709 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 532,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. F1 · shares: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. Read SEC document |
| August 17, 2023 Filed Aug 21, 2023 20:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 4,767 | $15.47 | $73,750.26 |
DisclosureSEC source: 0001140361-23-040694 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 524,854 F1 · security: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person. F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person. Read SEC document |
| August 14, 2023 Filed Aug 15, 2023 20:06 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 7,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-039901 · form4.xml · derivative · entry 4 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,877 Underlying: Common Stock · 7,979 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. F3 · derivative.expiration_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| August 14, 2023 Filed Aug 15, 2023 20:06 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 7,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-039901 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 529,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. F1 · shares: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 23:01 UTC | Tourmaline Bio, Inc. TALS · Entity 15643 | GrantStock Option (Right to Buy) · Derivative | 20,500 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001209191-23-037190 · doc4.xml · derivative · entry 1 Shah Gaurav · CIK 0001725922 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2033-06-13 F1 · derivative.exercise_date: The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 4,122 | $21.38 | $88,107.75 |
DisclosureSEC source: 0001140361-23-025742 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 521,642 F1 · security: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person. F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person. Read SEC document |
| May 14, 2023 Filed May 17, 2023 00:04 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 7,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-025133 · form4.xml · derivative · entry 4 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,856 Underlying: Common Stock · 7,979 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. F3 · derivative.expiration_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| May 14, 2023 Filed May 17, 2023 00:04 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 7,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-025133 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 525,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. F1 · shares: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 00:27 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 12,194 | $19.06 | $232,417.64 |
DisclosureSEC source: 0001140361-23-008102 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 536,885 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person. F2 · price: This transaction was executed in multiple brokered trades at prices ranging from $18.735 to $19.195. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:45 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantRestricted Stock Units · Derivative | 116,317 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-007482 · form4.xml · derivative · entry 2 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,317 Underlying: Common Stock · 116,317 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. F3 · derivative.expiration_date: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:45 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 348,590 | $0.00 Strike: $20.04 | $0.00 |
DisclosureSEC source: 0001140361-23-007482 · form4.xml · derivative · entry 1 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,590 Underlying: Common Stock · 348,590 shares Expires 2033-02-13 F1 · derivative.exercise_date: This option represents a right to purchase a total of 348,590 shares of the Issuer's common stock, one-third (1/3) of which will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2023 Filed Feb 23, 2023 00:25 UTC Amendment | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 31,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-008098 · form4.xml · derivative · entry 6 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,835 Underlying: Common Stock · 31,440 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The original Form 4, filed on February 16, 2023, is being amended by this amendment to include the vesting of restricted stock units that took place on February 14, 2023. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: One-third (1/3) of such restricted stock units became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. F6 · derivative.expiration_date: One-third (1/3) of such restricted stock units became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2023 Filed Feb 23, 2023 00:25 UTC Amendment | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantRestricted Stock Units · Derivative | 116,317 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-008098 · form4.xml · derivative · entry 5 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,317 Underlying: Common Stock · 116,317 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. F5 · derivative.expiration_date: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2023 Filed Feb 23, 2023 00:25 UTC Amendment | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 348,590 | $0.00 Strike: $20.04 | $0.00 |
DisclosureSEC source: 0001140361-23-008098 · form4.xml · derivative · entry 4 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,590 Underlying: Common Stock · 348,590 shares Expires 2033-02-13 F3 · derivative.exercise_date: This option represents a right to purchase a total of 348,590 shares of the Issuer's common stock, one-third (1/3) of which will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2023 Filed Feb 23, 2023 00:25 UTC Amendment | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 31,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-008098 · form4.xml · nonDerivative · entry 1 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 549,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The original Form 4, filed on February 16, 2023, is being amended by this amendment to include the vesting of restricted stock units that took place on February 14, 2023. F2 · shares: Represents shares of Common Stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 14, 2023 Filed May 20, 2024 20:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | OtherRestricted Stock Units · Derivative | 67,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-026878 · form4.xml · derivative · entry 11 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,947 shares Expires not disclosed F2 · security: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · kind: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F2 · derivative.exercise_date: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F2 · derivative.expiration_date: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2023 Filed May 20, 2024 20:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | OtherCommon Stock | 67,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-026878 · form4.xml · nonDerivative · entry 4 Shah Gaurav · CIK 0001725922 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 737,859 F2 · security: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F3 · security: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F3 · kind: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.